Revolution Medicines
RVMD
696 hedge funds and large institutions have $40.1B invested in Revolution Medicines in 2026 Q2 according to their latest regulatory filings, with 246 funds opening new positions, 241 increasing their positions, 149 reducing their positions, and 62 closing their positions.
297% more first-time investments, than exits
New positions opened: 246 | Existing positions closed: 62
89% more call options, than puts
Call options by funds: $741M | Put options by funds: $391M
86% more capital inflows, than outflows
Capital inflows: $8.35B | Capital outflows: $4.49B
62% more repeat investments, than reductions
Existing positions increased: 241 | Existing positions reduced: 149
35% more funds holding
Funds holding: 515 → 696 (+181)
2% more funds holding in top 10
Funds holding in top 10: 46 → 47 (+1)
0.6% more ownership
Funds ownership: 100.05% → 100.66% (+0.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$1.23B |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$585M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$546M |
| 4 |
JP Morgan Chase
New York
|
+$438M |
| 5 |
BlackRock
New York
|
+$363M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$713M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$319M |
| 3 |
Vestal Point Capital
New York
|
-$281M |
| 4 |
Abu Dhabi Investment Council
Abu Dhabi,
United Arab Emirates
|
-$234M |
| 5 |
Logos Global Management
San Francisco,
California
|
-$190M |
RVMD Hedge Fund Activity: Q2 2026 in Review
696 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in Revolution Medicines (RVMD) for Q2 2026, worth a combined $40.1B — up 111% from $19.1B a quarter earlier.
Buyers outnumbered sellers: 246 funds opened new RVMD positions and 62 closed out — a net gain of 184 holders — while 241 added to existing stakes and 149 trimmed.
The largest buyer was Darwin Global Management, adding an estimated $1.23B. The largest seller was Adage Capital Partners, cutting an estimated $713M.
- 696 institutional investors held Revolution Medicines (RVMD) as of Q2 2026, up from 515 in Q1 2026.
- Funds reported $40.1B of Revolution Medicines stock for Q2 2026, up 111% quarter-over-quarter.
- 246 funds opened new Revolution Medicines positions in Q2 2026 and 62 closed out, a net change of +184 holders.
- The largest Revolution Medicines buyer in Q2 2026 was Darwin Global Management, an estimated $1.23B added.
- The largest Revolution Medicines seller in Q2 2026 was Adage Capital Partners, an estimated $713M sold.
Based on aggregated 13F filings for Q2 2026.